Long-Sheng Chang

Long-Sheng Chang

Auto-generated profile, based on publicly available information

Long-Sheng Chang

Center for Childhood Cancer, Abigail Wexner Research Institute, Nationwide Children’s Hospital and Department of Pediatrics, The Ohio State University, Columbus, OH 43215, USA

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2012 in Cell
Verified
Journal Article
Closed access
YWYuan Wang
Yuan Wang
EKEdward Kim
Edward Kim
XWXiaojing Wang
Xiaojing Wang
BNBennett G. Novitch
Bennett G. Novitch
KYKazuaki Yoshikawa
Kazuaki Yoshikawa
YZYuan Zhu
Yuan Zhu

21 July 2011 in Neuro-Oncology
Verified
Journal Article
Closed access
MBM. L. Bush
M. L. Bush
JOJ. Oblinger
J. Oblinger
VBV. Brendel
V. Brendel
GSG. Santarelli
G. Santarelli
JHJ. Huang
J. Huang
AJA. Jacob
A. Jacob
Neurofibromatosis type 2 (NF2) is an autosomal-dominant disease that results in the formation of bilateral vestibular schwannomas (VSs) and multiple meningiomas. Treatment options for NF2-associated tumors are limited, and to date, no medical therapies are FDA approved. The ideal chemotherapeutic agent would inhibit both VS and meningiomas simultaneously. The objectives of this study are (1) to test the efficacy of AR42, a novel histone deacetylase inhibitor, to inhibit VS and meningioma growth and (2) to investigate this drug's mechanisms of action. Primary cultures of human VS and meningioma cells were established. Nf2-deficient mouse schwannoma and benign human meningioma Ben-Men-1 cells were also cultured. Cells were treated with AR42, and the drug's effects on proliferation and the cell cycle were analyzed using a methanethiosulfonate assay and flow cytometry, respectively. Human phospho-kinase arrays and Western blots were used to evaluate the effects of AR42 on intracellular signaling. The in vivo efficacy of AR42 was investigated using schwannoma xenografts. Tumor volumes were quantified using high-field, volumetric MRI, and molecular target analysis was performed using immunohistochemistry. AR42 inhibited the growth of primary human VS and Nf2-deficient mouse schwannoma cells with a half maximal inhibitory concentration (IC(50)) of 500 nM and 250-350 nM, respectively. AR42 also inhibited primary meningioma cells and the benign meningioma cell line, Ben-Men-1, with IC(50) values of 1.5 µM and 1.0 µM, respectively. AR42 treatment induced cell-cycle arrest at G(2) and apoptosis in both VS and meningioma cells. Also, AR42 exposure decreased phosphorylated Akt in schwannoma and meningioma cells. In vivo treatment with AR42 inhibited the growth of schwannoma xenografts, induced apoptosis, and decreased Akt activation. The potent growth inhibitory activity of AR42 in schwannoma and meningioma cells suggests that AR42 should be further evaluated as a potential treatment for NF2-associated tumors.

10 January 2008 in BMC Cell Biology
Verified
Journal Article
Open access
PDF file
NDNatalia V Dorogova
Natalia V Dorogova
EAElena M Akhmametyeva
Elena M Akhmametyeva
SKSergei A Kopyl
Sergei A Kopyl
NGNatalya Gubanova
Natalya Gubanova
OYOlga S Yudina
Olga S Yudina
LCLong-Sheng Chang
Long-Sheng Chang
Drosophila Merlin, the homolog of the human Neurofibromatosis 2 (NF2) gene, is important for the regulation of cell proliferation and receptor endocytosis. Male flies carrying a Mer3 allele, a missense mutation (Met177→Ile) in the Merlin gene, are viable but sterile; however, the cause of sterility is unknown.

1 June 2009 in European Journal of Cancer
Verified
Journal Article
Closed access
TLTina X. Lee
Tina X. Lee
MPMark D. Packer
Mark D. Packer
JHJie Huang
Jie Huang
EAElena M. Akhmametyeva
Elena M. Akhmametyeva
SKSamuel K. Kulp
Samuel K. Kulp
LCLong-Sheng Chang
Long-Sheng Chang

15 July 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LCLong-Sheng Chang
Long-Sheng Chang
JOJanet L. Oblinger
Janet L. Oblinger
ASAbbi E. Smith
Abbi E. Smith
MFMarc Ferrer
Marc Ferrer
SASteven P. Angus
Steven P. Angus
DCD. Wade Clapp
D. Wade Clapp
Neurofibromatosis Type 2 (NF2) is an autosomal dominant genetic syndrome caused by mutations in the NF2 tumor suppressor gene resulting in multiple schwannomas and meningiomas. There are no FDA approved therapies for these tumors and their relentless progression results in high rates of morbidity and mortality. Through a combination of high throughput screens, preclinical in vivo modeling, and evaluation of the kinome en masse, we identified actionable drug targets and efficacious experimental therapeutics for the treatment of NF2 related schwannomas and meningiomas. These efforts identified brigatinib (ALUNBRIG®), an FDA-approved inhibitor of multiple tyrosine kinases including ALK, to be a potent inhibitor of tumor growth in established NF2 deficient xenograft meningiomas and a genetically engineered murine model of spontaneous NF2 schwannomas. Surprisingly, neither meningioma nor schwannoma cells express ALK. Instead, we demonstrate that brigatinib inhibited multiple tyrosine kinases, including EphA2, Fer and focal adhesion kinase 1 (FAK1). These data demonstrate the power of the de novo unbiased approach for drug discovery and represents a major step forward in the advancement of therapeutics for the treatment of NF2 related malignancies.

15 January 2013 in Cancer Research
Verified
Journal Article
Closed access
PDF file
SBSarah S. Burns
Sarah S. Burns
EAElena M. Akhmametyeva
Elena M. Akhmametyeva
JOJanet L. Oblinger
Janet L. Oblinger
MBMatthew L. Bush
Matthew L. Bush
JHJie Huang
Jie Huang
LCLong-Sheng Chang
Long-Sheng Chang
Meningiomas constitute about 34% of primary intracranial tumors and are associated with increased mortality in patients with neurofibromatosis type 2 (NF2). To evaluate potential medical therapies for these tumors, we have established a quantifiable orthotopic model for NF2-deficient meningiomas. We showed that telomerase-immortalized Ben-Men-1 benign meningioma cells harbored a single nucleotide deletion in NF2 exon 7 and did not express the NF2 protein, merlin. We also showed that AR-42, a pan-histone deacetylase inhibitor, inhibited proliferation of both Ben-Men-1 and normal meningeal cells by increasing expression of p16INK4A, p21CIP1/WAF1, and p27KIP1. In addition, AR-42 increased proapoptotic Bim expression and decreased anti-apoptotic BclXL levels. However, AR-42 predominantly arrested Ben-Men-1 cells at G2–M whereas it induced cell-cycle arrest at G1 in meningeal cells. Consistently, AR-42 substantially decreased the levels of cyclin D1, E, and A, and proliferating cell nuclear antigen in meningeal cells while significantly reducing the expression of cyclin B, important for progression through G2, in Ben-Men-1 cells. In addition, AR-42 decreased Aurora A and B expression. To compare the in vivo efficacies of AR-42 and AR-12, a PDK1 inhibitor, we generated and used luciferase-expressing Ben-Men-1-LucB cells to establish intracranial xenografts that grew over time. While AR-12 treatment moderately slowed tumor growth, AR-42 caused regression of Ben-Men-1-LucB tumors. Importantly, AR-42–treated tumors showed minimal regrowth when xenograft-bearing mice were switched to normal diet. Together, these results suggest that AR-42 is a potential therapy for meningiomas. The differential effect of AR-42 on cell-cycle progression of normal meningeal and meningioma cells may have implications for why AR-42 is well-tolerated while it potently inhibits tumor growth. Cancer Res; 73(2); 792–803. ©2012 AACR.